IL37 and autoimmune disease: In conclusion, the recent evaluations on the therapeutic use of IL-23 seem to have two advantages: on the one hand, the possibility that IL-23 could represent a valid marker for the initial stages of autoimmune diseases, and, on the other, the possibility of identifying pharmacological treatments that specifically modulate the T helper’s immune response [94].